Douglas M. Hunt - Jul 8, 2025 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role: The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Signature: /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt
Stock symbol: PBYI
Transactions as of: Jul 8, 2025
Transactions value $: -$27,624
Form type: 4
Date filed: 7/10/2025, 08:52 PM
Previous filing: Feb 11, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HUNT DOUGLAS M	The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES	/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt	2025-07-10	0001727172

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PBYI	Common Stock	Sale	-$15.5K	-4.37K	-2.53%	$3.53	168K	Jul 8, 2025	Direct	F1
transaction	PBYI	Common Stock	Sale	-$12.2K	-3.44K	-2.05%	$3.54	165K	Jul 9, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.